Vaccine Scheduler
Meningococcal Disease: Recommended vaccinations
| General recommendation | |
| Recommendation for specific groups only | |
| Catch-up (e.g. if previous doses missed) | |
| Vaccination not funded by the National Health system | |
| Mandatory vaccination |
| Weeks | Months | Years | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 2 | 3 | 4 | 5 | 6 | 10 | 11 | 12 | 13 | 14 | 15 | 2 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 24 | 29 | ≥ 30 | |||
| Austria | MenB1 | MenB | MCV4/MenB | MCV4 | ||||||||||||||||||||||||
| Belgium | MCV4 | MCV42 | ||||||||||||||||||||||||||
| Bulgaria | ||||||||||||||||||||||||||||
| Croatia | MCV4/MenB3 | |||||||||||||||||||||||||||
| Cyprus | MCV4 | MPSV44 | ||||||||||||||||||||||||||
| Czechia | MenB5 | MenB5 | MCV4/MenB5 | MCV4/MenB5 | MCV4/MenB5 | |||||||||||||||||||||||
| Denmark | ||||||||||||||||||||||||||||
| Estonia | ||||||||||||||||||||||||||||
| Finland | MCV46 | MCV4/MenB7 | MCV4/MenB8 | MenB9 | MCV410 | |||||||||||||||||||||||
| France | MenB11 | MenB | MCV412 | MCV4/MenB | MCV413 | MCV4/MenB | ||||||||||||||||||||||
| Germany | MenB14 | MenB14 | MenB14 | MCV414 | MCV414 | |||||||||||||||||||||||
| Greece | MenB | MenB | MenC15 | MenB | MCV4 | MCV4 | MCV4/MenB | |||||||||||||||||||||
| Hungary | MenC | MenC | MenC16 | |||||||||||||||||||||||||
| Iceland | MCV4 | |||||||||||||||||||||||||||
| Ireland | MenB | MenB | MenB | MenC | MCV4 | |||||||||||||||||||||||
| Italy | MenB17 | MenB17 | MCV4 | MenB17 | MenB17 | MCV418 | ||||||||||||||||||||||
| Latvia | ||||||||||||||||||||||||||||
| Liechtenstein | MCV419 | MCV420 | ||||||||||||||||||||||||||
| Lithuania | MenB | MenB | MenB21 | |||||||||||||||||||||||||
| Luxembourg | MenB | MenB | MenB | MCV4 | MCV422 | MCV423 | ||||||||||||||||||||||
| Malta | MenB | MCV4 | MenB | MenB | MCV4 | MCV4 | ||||||||||||||||||||||
| Netherlands | MCV424 | MCV424 | ||||||||||||||||||||||||||
| Norway | ||||||||||||||||||||||||||||
| Poland | MCV4/MenB25 | |||||||||||||||||||||||||||
| Portugal | MenB | MenB | MCV4/MenB | |||||||||||||||||||||||||
| Romania | ||||||||||||||||||||||||||||
| Slovakia | ||||||||||||||||||||||||||||
| Slovenia | ||||||||||||||||||||||||||||
| Spain | MenB26 | MenB - MenC26 | MenB - MenC26 | MCV427 | MCV428 | |||||||||||||||||||||||
| Sweden | ||||||||||||||||||||||||||||
Footnotes:
- MenB vaccination is recommended as early as possible from the age of 2 months and not funded. Catch-up vaccinations are recommended up to the age of 25. MenACWY vaccination is recommended as early as possible at the age of 13 months and not funded. One dose of the tetravalent conjugated meningococcal vaccine is recommended between the ages of 10-13 and funded. Additionally, please refer to official recommendations for timing and number of doses required according to age: https://www.sozialministerium.gv.at/impfplan (p. 77ff)
- Adolescent dose recommended but not implemented in free vaccination programs
- Vaccination is recommended and funded by Croatian Health Insurance for certain at risk groups, both MenB and MenACWY (children and adults - for example: splenectomized individuals, people after HSCTs, persons with disorders of complement components, including those receiving eculizumab or ravulizumab therapy)
- vaccines only given on specific indications
- MenB vaccination for infants is covered by health insurance if the schedule is started before the age of 1 year, and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. MCV4 vaccination for toodlers is covered by health insurance if is administered at the age interval from 12 to 23 months and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. Vaccination with MenB and MCV4 vaccines is covered by health insurance for persons of all ages with immune disorders. More details of the recommendation is available at: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-ceske-vakcinologicke-spolecnosti-cls-jep-pro-ockovani-proti-invazivnim-meningokokovym-2
- MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote
- MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote MenB: Bexsero vaccine is administered to infants aged 2 to 5 months as a series of three doses, spaced at least one month apart. A booster dose is then recommended at 12 to 15 months of age, provided that at least six months have passed since the last dose. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
- Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
- Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
- A MCV4 dose is administered to military conscripts upon commencement of their service (compulsory for men and voluntary for women). While the majority begin service between the ages of 19 and 20, the official age range for enlistment spans from 18 to 29 years.
- Vaccination introduced in 2022. Mandatory since January 2025.
- Introduced in January 2025 in replacement of monovalent MenC
- More information available at: https://www.service-public.fr/particuliers/actualites/A16520
- For MenB, according to the product information, the vaccination series consists of 3 vaccine doses for children aged 2–23 months and 2 vaccine doses for children aged 24 months and older. For MenACWY, recommendation in October 2025 to vaccinate at age 12-14 (up until age 24) and recommendation against MenC vaccination for infants and small children
- MenC: 1 dose at the age of 10 months
- Since January 1st, 2017, the meningococcal C vaccine is offered to all children aged under 2 years with 100% reimbursement on a voluntary-based approach.
- Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
- Meningococcal ACWY, one dose for adolescents age 12-18
- Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 5 years of age.
- Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 20 years of age.
- Can be administered concomitantly with MMR
- Booster dose of vaccine against invasive meningococcal disease ACWY
- Catch-up recommendation for those at increased risk of complications or severe disease also after the age of the general recommendation (https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/202300606-vaccination-contre-le-menincocoques-mj-2023-vf.pdf)
- Also prescribed to medical high risk groups of other ages by the attending medical doctor and reimbursed by the health insurer (https://lci.rivm.nl/factsheets/meningokokken-acwy-vaccinatie)
- Men B and Men ACWY vaccines recommended and refunded only in risk groups for people aged 12 months - 18 years
- Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
- One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
- The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm